

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ROPIVACAINE LONG-ACTING INJECTION (SYH9089 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Ropivacaine Long-acting Injection (SYH9089 Injection) (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product can block the influx of sodium ions into the cell membrane of nerve fibers by inhibiting sodium ion channels in nerve cells, thereby exerting a reversible blockade of impulse conduction along nerve fibers. Additionally, it can reduce the dosing frequency, meet the clinical need for continuous post-operative analgesia, decrease patients’ reliance on opioid medications, and avoid the risks of infection or displacement associated with continuous analgesia devices, significantly improving treatment adherence and medication safety. Leveraging the Group’s long-acting drug delivery technology platform, the Product is capable of extending the analgesic duration of a single administration to one week, positioning it to potentially become the first ultra-long-acting analgesic product with an analgesic duration of one week in China.

Preclinical studies indicated that the Product exhibited no systemic toxicity or new toxic target organs, and compared with marketed ropivacaine injections, demonstrated a significant advantage in long-acting analgesic effect, with a favorable safety and efficacy profile.

The indication for this clinical trial approval is post-operative analgesia. The approval for the clinical trials of the Product is expected to address the urgent clinical need in the field of ultra-long-acting post-operative analgesia and represents an important achievement for the Group in the field of central nervous system.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 16 February 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.